Yangzijiang stormed the 15 billion contrast media market and won 9 provinces and cities at low prices

The fifth batch of centralized procurement will be launched in October.
The leading companies in contrast media lose their bids, and the "barefoot" companies win the bids.
The market is facing a major reshuffle
.
According to data from Menet.
com, the terminal contrast agent market for public medical institutions in China will exceed 15 billion yuan in 2020; among the TOP10 products, the first on the list has changed ownership for the first time; among the TOP10 brands, General Electric has 3 brands on the list, Hengrui Medicine, Yangzijiang Pharmaceutical, Bracco has two brands each on the list
.
At present, only three contrast agents have been reviewed, two of which have entered centralized procurement.
Yangzijiang Pharmaceutical won the bids at high and low prices respectively, and two new product listing applications are under review.
The competition with Hengrui Pharmaceuticals has intensified
.

15 billion contrast agent market! The
fifth batch of TOP10 products was released by Guoshui, which included the contrast agent for the first time, and the loss of the standard of iodixanol, the core product of Hengrui Pharmaceuticals, a leading domestic contrast agent enterprise, caused widespread concern in the industry
.
Contrast agent is one of the most commonly used drugs in interventional radiology operations, and its market scale has risen rapidly in recent years
.
According to data from Menet.
com, the sales of terminal contrast agents in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) rose from more than 6 billion yuan in 2013 to more than 150 in 2019 100 million yuan
.
Affected by the new crown epidemic, its sales fell slightly by 0.
64% in 2020
.
Among them, the market share of iodized salt X-ray contrast agents exceeds 80%
.
Sales of terminal contrast agents in China's public medical institutions (unit: 100 million yuan) Source: Mynet.
com China's public medical institutions' terminal competition landscape Among the top 10 contrast agents, 4 products have sales of more than 1 billion yuan
.
The top of the list changed hands for the first time.
Iodixanol injection ranked first with sales of more than 4 billion yuan.
Iohexol injection and ioverol injection ranked second and third respectively.

.
The sales of many products have declined, and the sales of iopamidol injection and iodobiol injection plummeted by 20%
.
Four products grew against the trend, gadoterate meglumine injection increased by 18.
95%, and iodixanol injection increased by 13.
90%
.
TOP10 Terminal Contrast Agent Products in China's Public Medical Institutions in 2020 Source: Menet.
com China's public medical institutions' terminal competition pattern Among the TOP10 contrast agent brands, six brands have sales of more than 1 billion yuan, and the market share of TOP3 brands exceeds 10%
.
General Electric has 3 brands on the list, and Hengrui Pharmaceuticals, Yangzijiang Pharmaceuticals, and Bracco each have 2 brands on the list
.
Among them, Hengrui Medicine's iodixanol injection ranked first with sales of more than 2 billion yuan
.
2020 China's public medical institution's terminal contrast agent brands TOP10 Source: Meinenet China's public medical institution's terminal competition pattern is the
　　first to imitate the collapse of the market, and the centralized procurement loses the standard! Hengrui's leading position is dangerous.

As a leading company in the domestic contrast agent market, Hengrui Pharmaceutical's market share has continued to expand in recent years.
The terminal of China's public medical institutions has risen from 12.
11% in 2013 to 28% in 2020
.
However, there are many hardships hidden behind the scenery
.
In April 2020, the first newspaper produced Hengrui Medicine gadobutrol injection to obtain medicines approval documents, approval of the conclusions is "not approve", and the first imitation pass
.
The product marketing application was undertaken by CDE in November 2012, and it took more than 7 years to complete the approval
.
Although the first imitation was blocked, Hengrui Medicine did not give up easily.
In May 2020, it quickly submitted an application for imitation of gadobutrol injection for 4 categories
.
At present, the first imitation is still expected, and if the gadobutrol injection is successfully approved, it can also be deemed to have passed the consistency evaluation
.
Centralized procurement is the fate of generic drugs.
As the two main players in the contrast agent market, iodixanol and iohexol are naturally not immune
.
However, it is not easy for Hengrui Medicine to over-evaluate iodixanol
.
In 2020, Stellite's iopamidol, iohexol, and iodixanol have been approved one after another and the first to be reviewed, and Zhengda Tianqing and Yangtze River's iodixanol have also been reviewed one after another
.
Seeing the over-evaluation of iodixanol by competitors and the inclusion of iodixanol in the fifth batch of centralized procurement, Hengrui Medicine's iodixanol will not be evaluated until April 21, 2021
.
On the day when the fifth batch of centralized procurement bids were opened, Hengrui Medicine's iodixanol unexpectedly failed the bid, which caused a sharp drop in the opening share price the next day
.
On July 1, Hengrui Pharmaceuticals issued a notice that some market divisions will be adjusted, and the market sales of some provinces, regions, and products will be handed over to the Imaging Business Department
.
Analysis believes that the adjustment may be related to the loss of iodixanol
.

　　Contrast agent centralized procurement 3 into 2 , Yangzijiang speeds up the market
due to high technical difficulty and few imitation companies .
Currently, only 3 types of contrast agents have passed/deemedly passed the consistency evaluation, including iohexol injection and iodixanol Injection, iopamidol injection
.
Among them, iodixanol and iohexol have been included in the fifth batch of centralized procurement
.
Due to the relatively small market size of iopamidol, and only Zhengda Tianqing and Stellite were the only reviewed companies when the centralized procurement catalog was released, they were not included in the centralized procurement
.
In June this year, the product of Kelun Pharmaceutical was approved and deemed to have been reviewed.
Only three companies have been reviewed.
Whether it will be included in the sixth batch of centralized procurement is worthy of attention
.
Contrast agent pass/deemed pass consistency evaluation source: Meinenet MED2.
0 China Drug Evaluation Database In the fifth batch of centralized procurement, General Electric Pharmaceuticals, Stellite's Iohexol injection 100ml: 30g (I) , 100ml: 35g (I), Iodixanol injection 100ml: 32g (I) were all winning the bid, Yangzijiang Pharmaceutical and Beilu Pharmaceutical's iohexol injection only won the bid for one specification
.
Iodixanol injection YangtzeRiver Pharmaceutical offer of 174.
8 yuan / bottle, the first successful pick obtained 9 provinces procurement amount
.
The fifth batch of centralized procurement of contrast media.
Source: Shanghai Sunshine Pharmaceutical Purchasing Network.
In this centralized procurement, the procurement cycle of iohexol injection is 2 years in principle, and the procurement cycle of iodixanol injection is 3 years
.
As a new player in the field of contrast agent preparations, Stellite is a big winner in the centralized procurement of contrast agents.
In 2020, the company's two specifications of iohexol injection achieved a total sales revenue of 518,100 yuan, and iodixanol injection did not form sales
.
Winning the bid for centralized procurement will help the company's products quickly open the domestic sales market and increase the company's market share
.
As one of the leading companies in the contrast agent market, Yangzijiang Pharmaceutical has adopted high and low price strategies for the two selected products
.
According to data from Meinnet.
com, the market share of Yangzijiang Pharmaceutical's terminal iohexol injection in public medical institutions in China in 2020 exceeds 50%.
The winning specification of 100ml: 30g (I) is its best-selling specification, and the winning unit price ( 106.
5 yuan/bottle) is higher than General Electric Pharmaceuticals (77.
53 yuan/bottle) and Stellite (88.
05 yuan/bottle)
.
Iodixanol injection Hengrui Medicine accounts for more than 50%, General Electric Pharmaceuticals accounts for nearly 29%, and Yangzijiang Pharmaceuticals accounts for nearly 12%
.
Regarding iodixanol injection, Yangtze River Pharmaceutical Co.
, Ltd.
quoted a price of 174.
8 yuan per bottle.
It won the bid with the first place and obtained purchases from 9 provinces, which is conducive to quickly grabbing Hengrui Medicine’s market.

.
It is worth noting that Yangzijiang Pharmaceutical also has two other contrast agents under review, including gadoterate meglumine injection and gadobutrol injection
.
The only domestic listed companies for gadoterate meglumine injection are Hengrui Pharmaceuticals and Gabor of France.
Hengrui Pharmaceuticals occupies nearly 80% of the market; no domestic imitation enterprise for gadobutrol injection has been approved, and Yangzijiang Pharmaceutical submitted a listing application in June this year.
, The progress lags behind Hengrui Pharmaceutical and Beilu Pharmaceutical
.
If these two varieties are approved for listing in the future, the competition between Yangzijiang Pharmaceutical and Hengrui Pharmaceuticals in the field of contrast agents will further intensify
.